Santhera Pharmaceuticals (SIX: SANN) reports financial results for the nine months ended September 30, 2018, and confirms its guidance and positive outlook. Read more
The company also announces the launch of an ordinary capital increase of up to 5,000,000 registered shares with a nominal value of CHF 1 each to be offered through an accelerated bookbuilding. Read more